Cingulate Therapeutics
Morristown, US · Delaware LLC
Find your way into Cingulate Therapeutics
55 people in our graph share verified history with the Cingulate Therapeutics team — schools, employers, funds. One of them is your warm intro.
Maija Slaidiņaunlockedknows Raul R Silva · together at New York University School of Medicine (overlapped)
×10knows the team · via Fairleigh Dickinson University
knows the team · via Ross University School of Medicine
Founders & leadership
SJ
Shane j SchafferFounder
LG
Louis George Van HornExecutive
RR
Raul R SilvainChief Science OfficerRaul Silva is Chief Science Officer at Cingulate Therapeutics. A child and adolescent psychiatrist with board certification in general, child and adolescent psychiatry, he previously held faculty positions at New York University School of Medicine as Associate Professor and Vice Chairman, served as Executive Director of Rockland Children's Psychiatric Center, and worked as Deputy Director in the Division of Child and Adolescent Psychiatry at Bellevue Hospital Center, with research and publication experience in psychopharmacology and the effects of stress and trauma on children and adolescents.
LA
Laurie A MyersExecutive
MN
Matthew N BramsinChief Medical Officer
CS
Craig Steven GilgallonExecutive
Board
PJ
Patrick J GallagherBoard director
AB
Arthur B StraughnBoard director
Reported raises · per SEC filings
Form D private placements$33M disclosed across 2 rounds · 2013
▶$26.2MraisedJun 2020 · 203 investors · PharmaceuticalsRule 506(b)
▶$26.2MraisedJun 2020 · 203 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Matthew N BramsExecutive Officer, Director
- Jeff ConroyDirector
- Louis George Van HornExecutive Officer
- Craig Steven GilgallonExecutive Officer
- Laurie A MyersExecutive Officer
- Raul R SilvaExecutive Officer
- Patrick J GallagherDirector
- Jeff HargrovesDirector
- Arthur B StraughnDirector
- Shane J SchafferExecutive Officer, Director
- Peter WerthDirector
- Amount sold
- $26.2M
- Minimum investment
- $100K
- Proceeds to insiders
- $1.3M
- First sale
- Nov 2013
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
▶$6.8MraisedJan 2018 · 116 investors · PharmaceuticalsRule 506(b)
▶$6.8MraisedJan 2018 · 116 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Louis George Van HornExecutive Officer
- Raul R SilvaExecutive Officer
- Laurie A MyersExecutive Officer, Director
- Matthew N BramsExecutive Officer, Director
- Shane j SchafferExecutive Officer, Director
- Patrick J GallagherDirector
- Craig Steven GilgallonExecutive Officer
- Arthur B StraughnDirector
- Amount sold
- $6.8M
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- Nov 2013
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded Cingulate Therapeutics?
- Cingulate Therapeutics was founded by Shane j Schaffer.
- How much funding has Cingulate Therapeutics raised?
- Cingulate Therapeutics has disclosed $33M raised across 2 rounds.
- Where is Cingulate Therapeutics headquartered?
- Cingulate Therapeutics is headquartered in Morristown, US.